Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis.
Anna RoskillyAmy HicksEleanor J TaylorRebecca JonesRichard ParkerDenis MoirPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
The FPR in placebo-treated participants in RCTs is lower than that described from observational data. Slower fibrosis progression predicts fewer persons with NASH will progress to cirrhosis than previously estimated.